Electra Therapeutics, Inc. (ETRA)

Electra Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Income Operating Income Growth	-86.75	-61.89	-26.32
Net Income Net Income Growth	-95.2	-61.98	-24.79
Earnings Per Share EPS Growth	-2163.66	-1408.52	-563.32
EPS Growth	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Cash & Investments Cash & Investments Growth	97.73	86.52	15.79
Total Debt Total Debt Growth	1.98	2.09	-
Net Cash (Debt) Net Cash Growth	95.74	84.43	15.79
Net Cash Growth	-	434.88%	-
Net Cash Per Share Net Cash Per Share Growth	2175.95	1918.89	358.75

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Cash Flow Operating Cash Flow Growth	-74.68	-60.48	-26
Capital Expenditures CapEx Growth	-0.64	-0.73	-
Free Cash Flow Free Cash Flow Growth	-75.32	-61.22	-26
Free Cash Flow Growth	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Aug 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 23, 2026

Data Sources Report a data error